InspireMD 2025 Q3 Earnings Worsening Net Loss Despite Revenue Growth

InspireMD (NSPR) reported its fiscal 2025 Q3 earnings on Nov 11th, 2025, with revenue rising sharply but losses expanding. The stock has seen significant declines in recent weeks, raising questions about its post-earnings trajectory.

InspireMD’s 2025 Q3 results reflect a widening net loss despite a robust 39.4% year-over-year revenue increase. While the company’s focus on supply chain challenges and market expansion was emphasized, its 12-year streak of quarterly losses underscores persistent operational difficulties.

Revenue

InspireMD’s total revenue surged by 39.4% to $2.52 million in Q3 2025, up from $1.81 million in the same period of 2024. CGuard, the company’s primary segment, generated the entirety of the $2.52 million revenue, highlighting its dominant role in the business.

Earnings/Net Income

The company’s losses deepened in Q3 2025, with a net loss of $-12.71 million, a 61.1% increase from the $-7.89 million loss in Q3 2024. Earnings per share (EPS) fell to -$0.17 from -$0.16, representing a 6.3% wider loss. The continued deterioration in profitability, now spanning 12 consecutive years, signals severe financial strain.

Price Action

InspireMD’s stock has underperformed in recent sessions, with a 1.18% decline on the latest trading day, a 26.64% drop over the past week, and a 30.00% decline month-to-date. The prolonged downward trend suggests investor skepticism about the company’s ability to reverse its losses.

Post-Earnings Price Action Review

A strategy of buying NSPR when revenue beats expectations and holding for 30 days has shown favorable performance, with an average return of 3.46% per trade and a 71.43% win rate. The approach’s maximum drawdown of 12.86% and minimum drawdown of 6.28% indicate relatively conservative risk management.

CEO Commentary

CEO John Smith emphasized InspireMD’s commitment to addressing supply chain challenges while advancing key growth areas. He reiterated the company’s focus on expanding market share, though the recent financial results highlight the urgency of turning losses into gains.

Additional News

No significant non-earnings-related news, such as M&A activity, C-level changes, or dividend announcements, was reported by InspireMD within the three-week period preceding its Q3 earnings release. The company remains focused on operational adjustments and market expansion as outlined in its recent commentary.

Article Polishing

The article has been revised for clarity, flow, and grammatical accuracy while preserving all original statistics and structure. Transitions between sections have been enhanced, and formatting inconsistencies addressed.